Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the ...

Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share ...

CAMBRIDGE, MA / ACCESS Newswire / October 13, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a ...

Billionaire biotech mogul Noubar Afeyan has called for urgent regulation of artificial intelligence agents that tech firms ...

Moderna MRNA shares suffered a sharp reversal on Friday, falling close to 10% after a strong October rally had pushed the ...

After a more than sevenfold YTD jump, Moderna (MRNA) fell nearly 10% in afternoon trading on Friday, becoming the biggest decliner in the S&P 500 (SP500) as investors await detailed results from a ...

Moderna shares gained 18% last week—finishing it at their highest level in more than four years—after the New York Times ...

Moderna (MRNA) stock has gained 282.6% over the past three months, outpacing a 4.1% return for the S&P 500. The shares ...

Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...

This stock has soared more than 600% this year.

Moderna (MRNA) has clearly outperformed after announcing an Oct. 24 presentation that will include additional late-stage trial data for its cancer shot developed with Merck (MRK), even as analysts ...

The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.